Cell and Gene Outsourcing
-
An Inside Look At Cell Therapy Services And Support
3/25/2024
“Services” and “support.” What do those words mean in the life science manufacturing industry? The truth is, they’re quite subjective—and relative to each company. Here’s how we define services and support at Cytiva.
-
De-Risking Drug Development With Organ-On-A-Chip Contract Research Services
3/25/2024
Delve into Emulate's variety of Organ-on-a-Chip services and tailored study design, supported by data-driven case studies showcasing its collaboration's impact on pharmaceutical decision-making.
-
Get To Know WuXi Advanced Therapies Testing Services
3/21/2024
Learn how we can help you move your pipeline forward, whether you manufacture with us at WuXi Advanced Therapies, in-house, or with one of our fellow CDMOs.
-
XOFLXâ„¢ Lenti Platform: Stable Lentiviral Vector Production Cell Lines Yield LVV Titres Comparable To The Four-Plasmid Process
3/21/2024
LVV manufacturing processes remain a significant hurdle for sponsors. Review the potential of a platform of packaging and producer cell lines designed to enhance LVV manufacturing efficiency.
-
Testing At WuXi Advanced Therapies
3/21/2024
Learn how a partner offering a comprehensive suite of integrated testing services designed to navigate the complexities of cell and gene therapies is critical for accelerating development timelines.
-
Fast Track Analysis For Pandemic Readiness: Approaches For Accelerated Adventitious Virus Testing In Viral Vector Vaccines
3/21/2024
Implementing NGS technology for adventitious virus testing in viral vector vaccine development and manufacturing is crucial for ensuring safety. Gain insights for an optimized sequencing method.
-
Manufacturing GTP And GMP
3/21/2024
Learn how a one-stop solution for your cell therapy needs can help ensure efficiency, cost-effectiveness, and faster patient treatment. Our Draw-to-Thaw® service streamlines the entire process.
-
Development And Optimization Of Suspension-Adapted 293T Cell Line
3/21/2024
Learn how an adapted cell line can reduce costs and improve scalability in the production of lentiviral vectors for CGTs and examine its potential to produce GMP-grade lentiviral vectors.
-
Navigating Regulatory Challenges For CGT Products In 2024 And Beyond
3/20/2024
The cell and gene therapy (CGT) regulatory landscape is complex and continuously evolving. Review expert insights based on recent FDA guidance as well as important considerations for CGT development.
-
How To Promote Batch-To-Batch Consistency In CAR-T Therapies
3/18/2024
Patient immune cells and varied raw materials introduce inherent biological variability into CAR-T therapy manufacturing, making it a constant balancing act of adjusting processes and technology to minimize batch-to-batch variability.